$IMVT

Girao Tiago sold $263K of IMVT

Girao Tiago (Chief Financial Officer) sold 6,798 shares of Immunovant, Inc. (IMVT) at $38.69 ($0.26M total) on 2026-07-23.

Original reporting
SEC EDGAR · Girao Tiago
Published Jul 24, 2026, 9:57 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 24, 2026, 10:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IMVT
Neutral
medium confidence
Mentioned
$IMVT
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IMVTNeutralLow
01

Why it matters

This provides a concrete datapoint on insider selling activity by the CFO, but it does not disclose any new company performance, guidance, or regulatory development.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a sustained repricing without accompanying fundamental news.

03

What to watch

Single insider sales are often noisy; traders should compare with prior Form 4 patterns and any concurrent company disclosures before inferring bearishness.

Relevance 4/10Novelty 3/10Timing: Filed after-hours on 2026-07-24, covering a sale executed on 2026-07-23.

Background

The article is a SEC Form 4 insider transaction disclosure for Immunovant, Inc.

Company-level read

Ticker impact

$IMVTNeutralMedium confidence
Context

Immunovant CFO Girao Tiago filed a Form 4 selling 6,798 shares at $38.69 on 2026-07-23 for about $263K.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional fundamental signal from this single sale.

Evidence & confidence

The filing is a primary-source Form 4, but it is a relatively small dollar amount and does not include new operating, regulatory, or financial guidance.

Market effects

No direct sector read-across; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

The absence of a stated 10b5-1 plan does not necessarily imply negative information; insiders may sell for diversification, taxes, or planned liquidity needs.

Key entities

  • Immunovant, Inc.

    US-listed company whose CFO filed the insider sale on Form 4.

  • Girao Tiago

    Chief Financial Officer who sold 6,798 shares at $38.69.

Related articles

$IMVTMed

Immunovant, Inc. (IMVT): Results of Operations and Financial Condition

Immunovant, Inc. (IMVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991202686.htm EX-99.1 Document Exhibit 99.1 Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 • All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves’ disease (GD),

$IMVTMedAI 9/10

H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data

H.C. Wainwright raised its Immunovant (IMVT) price target to $40 from $35 and kept a Buy rating after positive Phase 2 rheumatoid arthritis data, citing high response rates and suggesting FcRn differs from JAK/TNF therapies. It increased IMVT-1402 success odds to 55% (from 30%) and EV sales multiple to 10x (from 9x). BofA also lifted its target to $43 and peak sales forecast for IMVT-1402 to $6.8B from $5.5B.